EyePoint Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a U.S.-based biopharmaceutical company headquartered in Watertown, Massachusetts, United States. The company is focused on ophthalmology, with a specific emphasis on retinal disease and intraocular inflammation. For investors, EyePoint is best viewed as a specialty biotech rather than a broad diversified pharmaceutical company: its business model centers on developing, clinically de-risking, selectively commercializing, and ultimately monetizing proprietary long-acting drug-delivery technologies for the eye. The company’s history includes earlier corporate iterations and name changes, including its prior identity as pSivida Corp. before adopting the EyePoint Pharmaceuticals name in March 2018. That transition reflected a strategic shift toward a more focused retinal and ophthalmic franchise. EyePoint also maintains a manufacturing footprint in Northbridge, Massachusetts, which supports production control for specialized ophthalmic products and reinforces its U.S. operating base. EyePoint’s commercial portfolio has historically included DEXYCU, an intraocular dexamethasone suspension for postoperative inflammation following cataract surgery, and YUTIQ, a fluocinolone acetonide intravitreal insert for chronic non-infectious posterior uveitis. These marketed products illustrate the company’s expertise in sustained-release ophthalmic formulations. In competitive terms, EyePoint competes against both conventional injectable therapies and other drug-delivery approaches, and it seeks differentiation through dosing convenience, extended duration of action, and the potential to improve adherence and patient outcomes. The company’s next-generation value driver is DURAVYU™ (formerly EYP-1901), a vorolanib intravitreal insert built on EyePoint’s proprietary Durasert platform. DURAVYU is being developed as a sustained-delivery therapy for wet age-related macular degeneration and diabetic macular edema. Management has positioned it as a potentially differentiated retinal asset, with the ambition to improve treatment burden and support a more durable therapeutic effect. EyePoint also uses strategic partnerships outside the United States, including in Greater China through Ocumension Therapeutics, to broaden the potential commercial reach of its assets. Recent highlights have been clinically important. In 2025, EyePoint announced completion of enrollment in its pivotal Phase 3 program for DURAVYU in wet AMD, and also reported positive Phase 2 data in diabetic macular edema. Those milestones support the investment thesis around DURAVYU and the broader Durasert platform, although the company remains subject to meaningful clinical, regulatory, commercialization, and financing risk. Overall, EyePoint is a NASDAQ-listed U.S. specialty ophthalmology company with meaningful pipeline optionality, but it should still be assessed as an execution-sensitive clinical-stage story rather than a mature cash-generating platform.